We report the case of a woman with an ALK positive lung adenocarcinoma, who developed bilateral complex renal cysts 17 months after the introduction of treatment with crizotinib. Clinical investigation led to the conclusion that the cysts were due to anticancer drug. Regression of the renal cysts was observed one month after cessation of the crizotinib. This case illustrates that specific and little known toxicities can occur with these novel molecules which have entered use for the management of lung cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmr.2015.01.007 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!